» Articles » PMID: 25383264

PSEUDOXANTHOMA ELASTICUM: DIAGNOSTIC FEATURES, CLASSIFICATION, AND TREATMENT OPTIONS

Overview
Publisher Informa Healthcare
Date 2014 Nov 11
PMID 25383264
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Pseudoxanthoma elasticum (PXE), a multisystem orphan disease, clinically affects the skin, the eyes, and the cardiovascular system with considerable morbidity and mortality. The clinical manifestations reflect the underlying pathology consisting of ectopic mineralization of peripheral connective tissues.

Areas Covered: The diagnostic criteria of PXE include characteristic clinical findings, together with histopathology of accumulation of pleiomorphic elastic structures in the dermis with progressive mineralization, and the presence of mutations in the gene. PXE-like cutaneous changes can also be encountered in other ectopic mineralization disorders, including generalized arterial calcification of infancy (GACI) caused by mutations in the gene. In some cases, overlapping clinical features of PXE/GACI, associated with mutations either in or , have been noted. PXE demonstrates considerable inter- and intrafamilial heterogeneity, and consequently, accurate diagnosis is required for appropriate classification with prognostic implications. There is no effective and specific treatment for the systemic manifestations of PXE, but effective therapies to counteract the ocular complications are in current clinical use.

Expert Opinion: A number of observations in the murine model, the mouse, have indicated that the mineral composition of diet, particularly the magnesium content, can influence the severity of the mineralization phenotype. These observations suggest that appropriate dietary interventions, coupled with lifestyle modifications, including smoking cessation, might alleviate the symptoms and improve the quality of life of individuals affected with this, currently intractable, orphan disease.

Citing Articles

Choroidal neovascularization secondary to angioid streaks in a patient with pseudoxanthoma elasticum: case report.

Beuran D, Constantin C, Serban R, Eftimie L, Cornacel C Rom J Ophthalmol. 2025; 68(4):470-475.

PMID: 39936052 PMC: 11809835. DOI: 10.22336/rjo.2024.85.


The PROPHECI trial: a phase II, double-blind, placebo-controlled, randomized clinical trial for the treatment of pseudoxanthoma elasticum with oral pyrophosphate.

Clotaire L, Rubera I, Duranton C, Gal J, Chamorey E, Humeau H Trials. 2025; 26(1):30.

PMID: 39881395 PMC: 11776210. DOI: 10.1186/s13063-024-08666-w.


Inorganic pyrophosphate plasma levels in patients with GGCX-associated PXE-like phenotypes.

Li Q, Troutman C, Peckiconis M, Wurst T, Terry S Front Genet. 2024; 15:1429320.

PMID: 39399214 PMC: 11466855. DOI: 10.3389/fgene.2024.1429320.


Comprehensive review of angioid streaks.

Kandasamy S, Shaikh N, Surve A, Kumari S, Bhayana A, Kumar P Indian J Ophthalmol. 2024; 73(Suppl 1):S47-S54.

PMID: 39257074 PMC: 11834907. DOI: 10.4103/IJO.IJO_812_24.


Cyclical Etidronate Reduces the Progression of Arterial Calcifications in Patients with Pseudoxanthoma Elasticum: A 6-Year Prospective Observational Study.

Harmsen I, van den Beukel T, Kok M, Visseren F, de Jong P, Papapoulos S J Clin Med. 2024; 13(16).

PMID: 39200754 PMC: 11354836. DOI: 10.3390/jcm13164612.


References
1.
Jansen R, Kucukosmanoglu A, De Haas M, Sapthu S, Otero J, Hegman I . ABCC6 prevents ectopic mineralization seen in pseudoxanthoma elasticum by inducing cellular nucleotide release. Proc Natl Acad Sci U S A. 2013; 110(50):20206-11. PMC: 3864344. DOI: 10.1073/pnas.1319582110. View

2.
Georgalas I, Tservakis I, Papaconstaninou D, Kardara M, Koutsandrea C, Ladas I . Pseudoxanthoma elasticum, ocular manifestations, complications and treatment. Clin Exp Optom. 2011; 94(2):169-80. DOI: 10.1111/j.1444-0938.2010.00559.x. View

3.
Li Q, Guo H, Chou D, Berndt A, Sundberg J, Uitto J . Mouse models for pseudoxanthoma elasticum: genetic and dietary modulation of the ectopic mineralization phenotypes. PLoS One. 2014; 9(2):e89268. PMC: 3929712. DOI: 10.1371/journal.pone.0089268. View

4.
Klement J, Matsuzaki Y, Jiang Q, Terlizzi J, Choi H, Fujimoto N . Targeted ablation of the abcc6 gene results in ectopic mineralization of connective tissues. Mol Cell Biol. 2005; 25(18):8299-310. PMC: 1234326. DOI: 10.1128/MCB.25.18.8299-8310.2005. View

5.
Wiegand T, Rogers A, McCabe F, Reichel E, Duker J . Intravitreal bevacizumab (Avastin) treatment of choroidal neovascularisation in patients with angioid streaks. Br J Ophthalmol. 2008; 93(1):47-51. DOI: 10.1136/bjo.2008.143461. View